Insight
TDXd
Dana-Farber’s Breast Oncology Center/X

The use of TDXd for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X:

“Check out our newest treatment guideline on the use of trastuzumab deruxtecan (TDXd) for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer.”

More posts featuring Dana-Farber’s Breast Oncology Center.

Breast Cancer cancer Dana-Farber’s Breast Oncology Center OncoDaily Oncology TDxd Trastuzumab deruxtecan treatment guideline